Medical network - on September 14, China's more than a dozen influential regional drug half 2017 results are clear, good overall performance, to withstand the pressure of the "two votes", many enterprises shows good ability to grow.
14 regional drug combined year-on-year growth rate of 12.24%, more than the 9.10% growth, "two votes" is popular all over the country can be achieved under the background of a rare double-digit year-on-year percentage of growth.
But most businesses grow through mergers and acquisitions, rather than real endogenous growth.
In any case, pharmaceutical business, especially the wholesale distribution industry, is about scale efficiency, and buying and buying is also the most direct way to expand market scale.
The 14 regional drugmakers' wholesale distribution income is not the same as the control of the family, but the growth momentum is strong
Although regional drugmakers mostly achieved good growth in the first half of 2017, the marketing network coverage and market size of national pharmaceutical companies such as state control, China resources and drug administration are not comparable to that of the market.
The 14 regional drugmakers' combined business income amounted to only 83.33 percent of the country's control of a company, but it also improved significantly from less than 75 percent in 2016. (editor's note, on April 24, this platform's article "data is all public, see 15 drugmakers", at that time the 15 companies counted only 75% of the company.)
The comparison of the basic performance of the 14 regional pharmaceutical companies in the 1-june 2017 period is as follows:
Note: data from companies listed semi-annual report for reference. Ranked the business income of regional drugmakers from January to June 2017. ? The total gross profit of the statistical reporting period was not recorded.
Can be seen from the data in the table 14 regional drug combined year-on-year growth rate of 12.24%, more than the 9.10% growth, "two votes" is popular all over the country can be achieved under the background of a rare double-digit year-on-year percentage of growth.
In 2017, there are six businesses with a year-on-year growth of more than 20 percent, and the health care and rukang medicine has increased by more than 50 percent, with runda medical treatment nearly doubling. Only the people of the two countries are in line with Thai and Chinese medicine.
Buying and buying is the gene code for the growth of these drugmakers
The breadth of network coverage with national drug companies and the advantages of the drug dealers in scale effect. From the perspective of business network coverage, the business of national drug dealers basically covers 31 provinces and cities of China, while the basic business scope of regional drug dealers is "a corner".
In terms of size, the country's big drugmakers are worth more than a dozen regional drugmakers, and regional drugmakers struggle to "look at it".
The main business coverage of the 14 regional drugmakers covers the following table:
Note: from public information collation, for reference.
But regional drug through capital m&a can also under the big stick of "two votes", the national several one hundred billion big drug giant cracks in looking for the opportunity to do bigger and stronger, where areas become a strong leader. A number of regional drugmakers have already started to do this, and several regional drugmakers have achieved rapid growth through continuous mergers and acquisitions.
Embellish of medical
So far, the company has established and acquired nearly 30 subsidiaries. Only in the first half of the year of 2017, the company through share purchase and investment cooperation, holding companies such as the southeast of Beijing, at the same time to capital increase, jinan, and other subsidiary companies such as taking a stake in the guangxi LiuRun. In addition, a non-public offering of shares and a payment of cash for a 100 per cent stake in riale is also planned.
Rui kang pharmaceutical
Rukang medicine based in shandong province, has formed a nationwide fire. At present, companies have combined more than 50 companies. The company accelerates the market layout through merger and acquisition integration and strategic cooperation. Among them, has great influence on the growth of the first half of 2017 subsidiary of mergers and acquisitions have xiamen jia son medical equipment co., LTD., xiamen PuXin biological technology co., LTD., yunnan gold snowland technology co., LTD., haikou bally, more than 10 companies such as trade co., LTD.
Fine things don
Through merger and acquisition, jiantang is moving forward to establish a national pharmaceutical sales network. Since 2014, the company successively guangzhou things best state medical equipment co., LTD., guangzhou jia yi nuclear medical technology co., LTD., Shanghai jia jia meaning about medical instrument co., LTD., zhejiang jia jayvo medical instrument co., LTD., sichuan jia xin and creamy medical equipment co., LTD., chongqing jia things become jump medical instrument co., LTD., shenzhen bay to reach technology co., LTD, etc.
tongjitang
Tongji has raised funds to accelerate the integration and expansion and the downstream extension through the establishment of m&a industry funds and issuing bonds. At present, the company's pharmaceutical distribution business has expanded to Beijing, jiangsu, anhui, jiangxi and other provinces, and actively seeks to acquire and acquire other pharmaceutical circulation enterprises. Tongjitang numerous subsidiaries, such as lohas tongjitang pharmaceutical co., LTD., xinjiang fruit and vegetable drinks the pharmaceutiacal market of biological products co., LTD., co., LTD., urumqi, xinjiang hops real estate development co., LTD., ala shan kou hops tongjitang silk road co., LTD., xinjiang pharmaceutical co., LTD., etc., many of them made by mergers and acquisitions.
How to achieve economic benefits after m&a? These companies need to think about it
In recent years, news that foreign companies have retreated from China and laid off workers has often been revealed, with more of them being pharmaceutical companies and research and development centers.
In July, news emerged that kantile, a multinational drug company, would sell its distribution operations in China for around 10 billion yuan.
At first, Kantian's rapid growth in distribution in China was rapid growth through buying and buying. Kant's music in China since 2007, speeded up the expansion in China, mainly on mergers and acquisitions way in hubei, chongqing, chengdu, wuxi, ningbo, shenzhen, dalian, guangzhou, tianjin and other dozens of cities to complete a publication.
No new progress has been made so far, but it is a sure thing to sell the business of the sector.
Kant to exit China distribution business, according to expert analysis after its acquisition of medicine wholesale enterprises in China, "two votes" opened in 2016, the wholesale business under pressure, difficult to determine the direction of the reform policy in China, so consider stripping the business in China.
Similarly, these regional drugmakers in China need to reflect on the risks of rapid market growth through mergers and acquisitions. These regional drugmakers realize the rapid growth of business by means of mergers and acquisitions, but there are also differences in the consistency of the market in the process of operation.
As a result, the company needs to adjust based on the characteristics of various regions, positive response to the test of cross-regional business, alert and prevent just income not ZengLi, even make enterprises are in a decline in net profit and loss situation.
|
